文献速递肝肾功能剂量调整特殊人群用药治疗药物监测与药物基因组学

甲氧苄啶/磺胺甲噁唑群体药代动力学:肾功能不全或CRRT患者剂量优化

Population Pharmacokinetics of Trimethoprim/Sulfamethoxazole: Dosage Optimization for Patients with Renal Insufficiency or Receiving Continuous Renal Replacement Therapy.
PubMed 文献 · Clin Pharmacol Ther · 2024-08-15

本研究基于168例住院患者348次TDM数据建立甲氧苄啶、磺胺甲噁唑及N-乙酰磺胺甲噁唑的群体药代动力学模型,并利用蒙特卡洛模拟优化肺孢子菌肺炎及肾功能不全或CRRT患者的复方磺胺甲噁唑给药方案。结果显示eGFR和CRRT影响清除率,肾功能不全需减量,CRRT患者需增加磺胺甲噁唑剂量。

要点

  • 无肾功能不全的肺孢子菌肺炎患者,复方磺胺甲噁唑TID 1,920 mg或BID 2,400 mg可达充分暴露。
  • eGFR 10 mL/min/1.73 m²需减量33.3%,eGFR 30 mL/min/1.73 m²需减量16.7%以达到等效暴露。
  • CRRT患者磺胺甲噁唑清除增加,需加倍剂量以达到等效暴露。

核心结论

  • eGFR和CRRT是所有三种化合物清除率的协变量,肾功能不全需减量,CRRT患者磺胺甲噁唑需加倍剂量。

研究设计与样本

  • 回顾性多中心观察性队列研究,基于住院患者复方磺胺甲噁唑TDM数据,共168例患者348次测量。

主要发现

  • eGFR和CRRT被纳入为甲氧苄啶、磺胺甲噁唑和N-乙酰磺胺甲噁唑清除率的协变量。
  • N-乙酰磺胺甲噁唑在eGFR降低患者中蓄积。
  • CRRT增加磺胺甲噁唑清除率,但不增加甲氧苄啶或N-乙酰磺胺甲噁唑的清除率。

关键数值与推荐

  • 无肾功能不全的肺孢子菌肺炎患者,复方磺胺甲噁唑TID 1,920 mg和BID 2,400 mg可达充分暴露。
  • eGFR 10 mL/min/1.73 m²患者需减量33.3%,eGFR 30 mL/min/1.73 m²患者需减量16.7%以达到等效暴露。
  • CRRT患者需加倍磺胺甲噁唑剂量以达到等效暴露。

临床怎么用

  • 临床应根据eGFR调整复方磺胺甲噁唑剂量,肾功能不全患者减量,CRRT患者增加磺胺甲噁唑剂量。
  • 接受复方磺胺甲噁唑治疗的患者应监测N-乙酰磺胺甲噁唑蓄积,尤其是eGFR降低者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The goal of the study was to describe the population pharmacokinetics of trimethoprim, sulfamethoxazole, and N-acetyl sulfamethoxazole in hospitalized patients. Furthermore, this study used the model to optimize dosing regimens of cotrimoxazole for Pneumocystis jirovecii pneumonia and in patients with renal insufficiency or with continuous renal replacement therapy (CRRT). This was a retrospective multicenter observational cohort study based on therapeutic drug monitoring (TDM) data from hospitalized patients treated with cotrimoxazole. We developed two population pharmacokinetic (POPPK) models: a model of trimethoprim and an integrated model with both sulfamethoxazole and N-acetyl sulfamethoxazole concentrations. Monte Carlo simulations were performed to determine the optimal dosing regimen. A total of 348 measurements from 168 patients were available. The estimated glomerular filtration rate (eGFR) and CRRT were included as covariates on the clearance of all three compounds. Cotrimoxazole TID 1,920 mg and b.i.d. 2,400 mg led to sufficient exposure for infections with P. jirovecii in patients without renal insufficiency. To reach equivalent exposure, a dose reduction of 33.3% is needed in patients with an eGFR of 10 mL/minute/1.73 m2 and of 16.7% for an eGFR of 30 mL/minute/1.73 m2. N-acetyl sulfamethoxazole accumulates in patients with a reduced eGFR. CRRT increased the clearance of sulfamethoxazole, but not trimethoprim or N-acetyl sulfamethoxazole, compared with the median clearance in the population. Doubling the sulfamethoxazole dose is needed for patients on CRRT to reach equivalent exposure.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Leegwater E, Baidjoe L, Wilms EB, et al. Population Pharmacokinetics of Trimethoprim/Sulfamethoxazole: Dosage Optimization for Patients with Renal Insufficiency or Receiving Continuous Renal Replacement Therapy. Clin Pharmacol Ther. 2024. PMID: 39148353. doi:10.1002/cpt.3421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。